Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Operating Expenses: 2019-2024

Historic Operating Expenses for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Dec 2024 value amounting to $494.8 million.

  • Maravai Lifesciences Holdings' Operating Expenses fell 76.40% to $46.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $464.3 million, marking a year-over-year increase of 4.34%. This contributed to the annual value of $494.8 million for FY2024, which is 54.34% up from last year.
  • Maravai Lifesciences Holdings' Operating Expenses amounted to $494.8 million in FY2024, which was up 54.34% from $320.6 million recorded in FY2023.
  • In the past 5 years, Maravai Lifesciences Holdings' Operating Expenses ranged from a high of $494.8 million in FY2024 and a low of $164.2 million during FY2020.
  • Moreover, its 3-year median value for Operating Expenses was $320.6 million (2023), whereas its average is $374.7 million.
  • Data for Maravai Lifesciences Holdings' Operating Expenses shows a peak YoY spiked of 54.34% (in 2024) over the last 5 years.
  • Over the past 5 years, Maravai Lifesciences Holdings' Operating Expenses (Yearly) stood at $164.2 million in 2020, then surged by 48.97% to $244.6 million in 2021, then increased by 26.24% to $308.8 million in 2022, then climbed by 3.82% to $320.6 million in 2023, then soared by 54.34% to $494.8 million in 2024.